Huntingdon slashing 100 jobs in U.K.; Clinical trial outcomes at the end of the world;

> Huntingdon Life Sciences, a U.K. CRO, is planning to cut 8% of its workforce, or about 100 jobs, to survive dwindling demand. News

> Indian regulators are considering forcing the closure of more than 50 pharma and CMO plants in Andhra Pradesh. Article

> S&P predicts that Quintiles can sustain its organic growth and snatch up even more market share in 2013. Story

> Avid Bioservices has completed all of its manufacturing upgrades, designed to help it commercialize Peregrine's bavituximab and Cotara. Item

> INC Research has notched its 500th QuickStart Camp enrollment, celebrating a program designed to help investigators plan accurate and efficacious studies. Release

> Presented with minimal comment: a Canadian Medical Association Journal analysis on how Mayan doomsday would (or will, if you're into that) affect outcomes in clinical trials. Study

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.